HOME >> MEDICINE >> NEWS
Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy

Late-breaking presentation shows multilineage blood cell growth with excellent safety in chemotherapy patients

Maret Pharmaceuticals, Inc. today reported positive Phase I/II clinical results that demonstrate the potential of MARstem™ as a multilineage hematopoietic therapy (multiple blood cell stimulant) to treat or prevent pancytopenia (a reduction in different types of blood cells) following chemotherapy in breast cancer patients. The study was selected as a late breaking abstract at the 11th National Cancer Institute - European Organization for Research and Treatment of Cancer - American Association for Cancer Research (NCI-EORTC-AACR) Symposium on New Drugs in Cancer Therapy.

The study was designed to evaluate safety, optimal dose and proof-of-principle efficacy of MARstem in adjuvant breast cancer patients. The results show that MARstem reduced the frequency of grade 2-4 thrombocytopenia (decrease in the number of blood platelets), grade 2-4 anemia (deficiency in red blood cells), and grade 3-4 lymphopenia (reduction in the number of lymphocytes) as compared to controls.

"These early clinical results suggest that MARstem may effective in improving or reducing the debilitating side effects of cancer treatment," said Terry Winters, Ph.D., Chairman and Chief Executive Officer of Maret Pharmaceuticals. MARstem has a clear therapeutic benefit as a multilineage hematopoietic factor as compared to traditional hematopoietic stimulants, which selectively increase only a single blood cell line. The trials outcome is promising, as the safety of MARstem has been established and the preliminary efficacy results are encouraging.

The studys results suggest that MARstem exhibits an excellent safety profile. There were no dose-limiting toxicities in the patients treated with MARstem. Specifically, there were no adverse cardiovascular or hematologic effects. The overall occurrence of side effects was lower in MARstem pa
'"/>

Contact: Heather Rosoff
hrosoff@fkhealth.com
617-761-6770
Feinstein Kean Healthcare
9-Nov-2000


Page: 1 2

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. Pharmaceuticals and personal care products
6. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
11. Hard choices: Pitt researcher presents findings on when to accept organ transplants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/20/2018)... , ... November 20, 2018 , ... VisionWare, a Civica ... payers and state and local government organizations, recently announced a 45-minute webinar that will ... value of MDM for payers and hospitals. It will also cover two case studies, ...
(Date:11/20/2018)... ... November 20, 2018 , ... The 2018-19 ski ... medicine specialist and USSA Ski Team Doctor Dr. Kevin Plancher, “you can’t start ... It’s a known fact that skiing and snowboarding are high-risk injury sports. According ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... acknowledging the organization as a behavioral service provider dedicated to continuous improvement ... in the areas of clinical quality, staff qualifications, and consumer satisfaction and ...
(Date:11/16/2018)... ... ... AP was selected in the Health Care 2 ($10-$30M) Category and will ... the Hyatt Regency Downtown Dallas along with other companies who have illustrated exceptional qualities ... the Annual Excellence in Construction National Level Competition through Associated Builders and Contractors, Inc ...
(Date:11/16/2018)... , ... November 16, 2018 , ... ... Kurapati's latest book Physician: How Science Transformed the Art of Medicine (GreenLeaf Press, ... in nonfiction health and medical. , Interweaving moving personal patient stories with ...
Breaking Medicine News(10 mins):
(Date:11/20/2018)... , ... November 20, 2018 , ... The holidays are ... Unfortunately there are many people who are cold and don't have the food ... members of the Association of NJ Chiropractors (ANJC) hold the annual "Baby It's Cold ...
(Date:11/18/2018)... ... November 18, 2018 , ... Millennials are creating ... , Some of their baby boomer parents have turned to fake trees as ... be authentic, natural, and meaningful. Their purchasing decisions and preferences are driving trends ...
(Date:11/17/2018)... ... November 17, 2018 , ... Getting ready for the holidays but ... aggravating inflammation, here’s good news: you certainly can enjoy the bounty of the season ... two things: what we eat and how much," says Ronald Stern, M.D., author of ...
Breaking Medicine Technology:
Cached News: